¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×Ü°æÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ O_*tDq,e  
D$`$4mX@hP  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© w=~X6[+3  
Z/OERO   
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© `U>]*D68  
O81'i2M J9  
1.Co-stimulators (or co-stimulating molecules) zGP@!R`_  
/K<>OyR?  
2.NK-kB Y*S(uqM  
m4R:K jN*  
3.Immunoglobulin superfamily $;)A:*e  
S AKIFNE  
4.antigen-presenting cell (APC) TR:4$92:H  
Bey9P)_O f  
5.death domain \{o<-S;h  
E .CG  
6.CCR and CXCR +,eF(VS!  
"[CR5q9Pr  
7.Lectin (or mitogen) W}WDj:  
ZD4:'m`T/  
8.Clusters of differentiation, CD) 9]g`VD6 <v  
=@d->d  
9.B7 family kU{a!ca4  
H9[0-Ur5  
10.Cytotoxic T lymphocyte, CTL) 2xv[cpVi  
gdg "g6b  
11.IL-15 and IL-15 receptor (IL-15R)  \ns} M3  
<#)Q.P  
12.MHC restriction P o\d!  
)vGxF}I3  
13.Affinity-chromatography ~8)l/I=`);  
D*g K,`  
14.Cyctosprin A, CsA GFvLd:p` [  
HgTBON(  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) {@[# 0gPH  
e[db?f2!  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© }eSrJgF4M  
~eXI}KhBw6  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿  *1 *i5c  
/lc4oXG8  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ !HF<fn  
&pH XSU  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌص㡣 6h1pPx7zU  
.qCI!%fg  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© i4)]lWnd  
<=%G%V_s  
ÃâÒßѧרҵ£º )qRE['M  
L#N ]1#;  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ /mK]O7O7  
C-H6l6,  
Ïû»¯ÄÚ¿Æ£º %Ybr5 $_  
XLlJ|xhY-K  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ J>fq5  
{&nDm$KTD  
ѪҺ²¡Ñ§×¨Òµ£º }s.\B    
u`pw'3hY  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÂÛ̳ÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»